HighTower Advisors
WHWK

HighTower Advisors’s Whitehawk Therapeutics WHWK Stock Holding History

HighTower Advisors’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,367
Closed -$46K – 2723
2020
Q2 		$46K Sell
2,367
-1,700
-42% -$22.2K ﹤0.01% 2200
2020
Q1 		$33K Hold
4,067
– – ﹤0.01% 2044
2019
Q4 		$39K Buy
4,067
+1,770
+77% +$14.8K ﹤0.01% 2138
2019
Q3 		$22K Sell
2,297
-200
-8% -$2.22K ﹤0.01% 2269
2019
Q2 		$33K Buy
2,497
+334
+15% +$5.07K ﹤0.01% 2237
2019
Q1 		$28K Buy
2,163
+466
+27% +$20K ﹤0.01% 2167
2018
Q4 		$43K Buy
1,697
+834
+97% +$26.6K ﹤0.01% 2041
2018
Q3 		$39K Buy
863
+30
+4% +$1.68K ﹤0.01% 2140
2018
Q2 		$52K Buy
+833
New +$50.4K ﹤0.01% 2062

Other funds holding WHWK

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
JIC
Johnson Investment Counsel Cincinnati, Ohio $12.4B AUM 17.21% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

HighTower Advisors's WHWK Position: Q3 2020 in Review

HighTower Advisors sold out of Whitehawk Therapeutics (WHWK) in Q3 2020, closing a stake of 2,367 shares — an estimated $46K sold.

HighTower Advisors first reported a position in WHWK in Q2 2018 and held it in 9 quarters. The position peaked at $52K in Q2 2018. 33 funds tracked by Wall St. Rank hold WHWK as of Q3 2020.

  • HighTower Advisors reported no remaining Whitehawk Therapeutics position as of Q3 2020 after selling out during the quarter.
  • HighTower Advisors sold 2,367 Whitehawk Therapeutics shares in Q3 2020, an estimated $46K.
  • HighTower Advisors first reported a position in Whitehawk Therapeutics in Q2 2018 and held it in 9 quarters.
  • HighTower Advisors's Whitehawk Therapeutics position peaked at $52K in Q2 2018.
  • 33 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q3 2020.

Based on HighTower Advisors's 13F filing for Q3 2020, filed 13 Nov 2020.